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BACKGROUND: Predicting the efficacy of antiangiogenic therapy would be of clinical value in patients (pts) with metastatic renal cell
carcinoma (mRCC). We tested the hypothesis that circulating endothelial cell (CEC), bone marrow-derived CD45
dimCD34
þ
VEGFR2
þ progenitor cell or plasma angiogenic factor levels are associated with clinical outcome in mRCC pts undergoing treatment
with tyrosine kinase inhibitors (TKI).
METHODS: Fifty-five mRCC pts were prospectively monitored at baseline (day 1) and day 14 during treatment (46 pts received
sunitinib and 9 pts received sorafenib). Circulating endothelial cells (CD45
 CD31
þCD146
þ7-amino-actinomycin (7AAD)
  cells)
were measured in 1ml whole blood using four-color flow cytometry (FCM). Circulating CD45
dimCD34
þVEGFR2
þ7AAD
 
progenitor cells were measured in progenitor-enriched fractions by four-color FCM. Plasma VEGF, sVEGFR2, SDF-1a and sVCAM-1
levels were determined by ELISA. Correlations between baseline CEC, CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cells, plasma
factors, as well as day 1–day 14 changes in CEC, CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor, plasma factor levels, and response
to TKI, progression-free survival (PFS) and overall survival (OS) were examined.
RESULTS: No significant correlation between markers and response to TKI was observed. No association between baseline CEC,
plasma VEGF, sVEGFR-2, SDF-1a, sVCAM-1 levels with PFS and OS was observed. However, baseline CD45
dimCD34
þ
VEGFR2
þ7AAD
  progenitor cell levels were associated with PFS (P¼0.01) and OS (P¼0.006). Changes in this population and in
SDF-1a levels between day 1 and day 14 were associated with PFS (P¼0.03, P¼0.002). Changes in VEGF and SDF-1a levels were
associated with OS (P¼0.02, P¼0.007).
CONCLUSION: Monitoring CD45
dimCD34
þVEGFR2
þ progenitor cells, plasma VEGF and SDF-1a levels could be of clinical interest in
TKI-treated mRCC pts to predict outcome.
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Metastatic renal cell carcinoma (mRCC) is generally resistant
to chemotherapy and hormonal therapy and marginally sensitive
to immunotherapy. Insights on the genetics and biology under-
lying RCC especially the role of the von Hippel-Lindau tumour-
suppressor gene (VHL), have provided the rationale to target this
pathway in VHL-deficient RCC and supported antiangiogenic
strategies in this disease (Rini and Small, 2005). Sunitinib is a
multitargeted tyrosine kinase inhibitor (TKI) of vascular endo-
thelial growth factor A receptors (VEGFRs), platelet-derived
growth factor receptors (PDGFRs), stem cell factor receptor
(KIT), glial cell-line-derived neurotrophic factor receptor
(rearranged during transfection), FMS-like tyrosine kinase-3
(FLT3) and the receptor for macrophage colony-stimulating factor
(CSF-1R) (Mendel et al, 2003). Sorafenib is a potent inhibitor
of Raf-1, a member of the RAF/MEK/ERK signalling pathway, and
of TKI receptors including VEGFRs, PDGFRs, FLT3 and KIT
(Wilhelm et al, 2004). Both antiangiogenic drugs have shown
clinical activity in metastatic clear-cell RCC and have been
approved worldwide for the treatment of metastatic RCC (Escudier
et al, 2007; Motzer et al, 2007).
Tumour vascularisation is dependent on the sprouting of blood
vessels with migration of endothelial cells and the recruitment of
mobilised bone marrow-derived (BMD) cells (Asahara et al, 1999).
Circulating endothelial cells (CECs) are mature cells detached from
vessel walls and high levels are observed in clinical diseases
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shallmarked by vascular insult including cancer (Blann et al, 2005;
Goon et al, 2006). Bone marrow-derived cells include several
categories of hematopoietic and vascular progenitors recruited to
sites of tumour neovascularisation in both cancer-bearing animals
(Lyden et al, 2001) and humans (Peters et al, 2005). One subset,
circulating endothelial progenitor cells (referred to as CEP), was
reported to incorporate into tumour neovessels (Lyden et al, 2001;
Spring et al, 2005; Nolan et al, 2007) and pre-clinical studies have
identified a critical role for these cells in promoting the angiogenic
switch and metastaticp r o g r e s s i o n( G a oet al, 2008). Although the
precise role of CEP as well as their phenotypic and functional
definition is still debated (Purhonen et al,2 0 0 8 ;Y o d e ra n dI n g r a m ,
2009), numerous studies have highlighted the importance of
interactions between hematopoietic (VEGFR1
þ) and endothelial
(VEGFR2
þ) BMD progenitor subsets in disease progression (Lyden
et al,2 0 0 1 ;P u r h o n e net al, 2008; Yoder and Ingram, 2009), and
vascularisation of metastatic lesions (Kaplan et al, 2005).
In clinical practice, the use of these vascular-targeted therapies is
challenged by the absence of validated biomarkers allowing to predict
response to treatment or toxic effects, select optimal dosage, or
elucidate potential mechanisms of action and resistance. Among
candidate biomarkers of antiangiogenic drugs, circulating BMD
progenitors (including CEP) and CEC measurements have raised
considerable interest (Jubb et al, 2006). However, because of technical
difficulties for their measurement, reliable data on their actual
prognostic or predictive value in cancer patients (pts) undergoing
antiangiogenic treatment are lacking (Strijbos et al, 2008). Also, despite
the fact that circulating levels of angiogenic growth factors generally
indicate poor prognosis, their significance in terms of predicting
antiangiogenic drug efficacy and clinical benefit is unclear.
In this study, we investigated whether the levels of CEC, of
CD45
dimCD34
þVEGFR2
þ progenitor cell subset as well as of
several proangiogenic/endothelial plasmatic factors (VEGF,
sVEGFR-2, SDF-1a, sVCAM-1), measured before and after 2 weeks
of therapy, are associated with clinical outcome in mRCC pts
undergoing TKI therapy.
PATIENTS AND METHODS
Patients and blood sample collection
All pts had mRCC and were treated at the Institut Gustave Roussy,
France, from October 2006 to January 2009. Patients received either
sunitinib or sorafenib as antiangiogenic treatment. Before treatment, all
pts had a detailed history, physical examination and baseline laboratory
parameters. Pretreatment baseline tumour status was evaluated with
CT scans of the brain, chest, abdomen and pelvis. Data collected
included standard demographics and disease characteristics, first date
of treatment, best response to treatment and date of progression, date
of death or last follow-up. Tumour evaluation was performed after
12 weeks of sunitinib or after 2–3 months of sorafenib. Responses were
documented according to Response Evaluation Criteria in Solid
Tumours (RECIST). Patients were followed by their physician (BE)
every 4–6 weeks. Informed consent was obtained for all pts. This
prospective study was approved by our institutional review board.
Peripheral blood sampling was performed at baseline day 1 (before
treatment initiation) and at day 14 of antiangiogenic therapy: 2ml of
whole blood was collected in Cellsave Preservative tubes (Immunicon,
Huntingdon Valley, PA, USA) for CEC analysis, and 10ml whole blood
was collected in standard heparin tubes for CD45
dimCD34
þ
VEGFR2
þ7AAD
  progenitor cell and plasmatic protein analysis.
Measurement of CD45
dimCD34
þVEGFR2
þ progenitor
cells
CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cells were measured
in 10ml of progenitor-enriched whole blood according to a
four-color FCM assay previously reported (Farace et al, 2007;
Taylor et al, 2009). Ficoll-gradient mononuclear cells were
enriched in progenitor cells using the RosetteSep antibody cocktail
(StemCell Technologies Inc., Vancouver, Canada). Progenitor-
enriched mononuclear cells were distributed into control and test
tubes and treated with FcR blocking reagent (Miltenyi Biotec,
Bergisch Gladbach, Germany). Staining was performed with
monoclonal antibodies CD45-FITC (clone T29/33, DakoCyto-
mation, Glostrup, Denmark), CD34-APC (clone BIRMA-K3, Dako
Cytomation), KDR-PE (clone 89106, R&D Systems, Minneapolis,
MN, USA) and 7AAD (BD Biosciences, San Jose, CA, USA).
Control tubes included a control PE tube (CD45-FITC/mouse
IgG1-PE/CD34-APC/7AAD) performed to measure accurately
background noise and to adjust the gates precisely. Cells were
acquired on a FACSCalibur (BD Biosciences). Data were analysed
using CELLQuest 3.2 software (BD Biosciences). Results were
expressed as the percentage of VEGFR2
þ cells among circulating
CD34
þprogenitor (CD45
dimCD34
þ7AAD
  and CD45
 CD34
þ
7AAD
 ) cells. The multigating strategy used to identify circulating
CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cells by four-color
FCM is shown in Supplementary Figure S1.
Measurement of CECs
Circulating endothelial cells were measured in 1ml whole blood by
four-color FCM according to a method we previously established
(Jacques et al, 2008). Immunofluorescent staining was performed
with monoclonal antibodies CD31 FITC (clone WM59, BD
Pharmingen, San Diego, CA, USA), CD146 PE (clone P1H12, BD
Pharmingen), CD45 APC (clone T29/33, DakoCytomation). An
IgG-PE control was performed in 0.5ml of whole blood (CD45-
APC/CD31-FITC/mouse IgG1-PE/7AAD) to measure background
noise and to adjust the gates precisely. All of the cells contained in
the IgG-PE control tube and in the CEC test tube were acquired,
representing approximately 2.5 10
6 events and 5 10
6 events,
respectively. Data were analysed using CELLQuest 3.2 software.
Using this method, we found that median CEC levels were 6.5ml
–1
(0–15ml
–1) in healthy adults (n¼20) and 16.0ml
–1(0–179ml
–1)
in pts with metastatic carcinoma (n¼125) (Po0.001) (Jacques
et al, 2008).
Plasmatic factors
Plasma levels of VEGF, sVEGFR-2, sVCAM-1 and SDF-1a were
determined using commercial ELISA kits (R&D Systems). Plasma
samples were assayed in duplicates. Optical density values were
considered significant if found to be at least twice as high as
background noise.
Statistical analysis
Correlation between markers and clinical response to treatment
(progressive vs non-progressive) were tested using the Wilcoxon–
Mann–Whitney test. The Wilcoxon signed-rank test was used to
test differences between marker levels at baseline and day 14.
Overall survival (OS) was calculated from the start of treatment
to the date of death or the last follow-up (censored data).
Progression-free survival (PFS) was calculated from the start of
treatment to the date of disease progression, death or the last
follow-up (censored data).
Overall survival and PFS rates were estimated using the Kaplan–
Meier method for survival curves. The relationships between
survival and the different markers were tested using the log-rank
test. The hazard ratios yielded by the Cox model were provided.
Values at baseline and day 14 were dichotomised according to
the third quartile cut-off. As levels of CD45
dimCD34
þVEGFR2
þ
cells in normal individuals and certain pts are very low (Taylor
et al, 2009) and close to the detection limit of the method used, a
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scut-off at a low or even at the median value might not have allowed
to discriminate pts with the highest risk vs pts with a lowest risk
because of an overlap between these two groups. We therefore
decided to select a threshold at two-thirds of the values and to
compare the third of the pts with the highest values with the
two-thirds remaining with lower values.
Variations between baseline and day 14 were classified as
increased, decreased or stable. All tests were two-sided and a
P-value o0.05 was considered statistically significant. The
statistical analysis was performed using SAS software (Release
9.1; SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics and baseline levels of CEC,
CD45
dimCD34
þVEGFR2
þ progenitor cells and plasma
proangiogenic factors
A total of 55 pts with mRCC were included in this study: 46 (84%)
pts received sunitinib and 9 pts (16%) received sorafenib. Tumour
histology (43 pts had clear cell renal carcinoma vs 12 with non-
clear cell), clinical characteristics at baseline and response to
treatment are presented in Table 1. A majority of pts received TKIs
as first-line therapy (38 out of 55). No patient reached a complete
response after treatment. The partial response rate to treatment
was 19% (10 pts). Stable disease was achieved in 28 pts (53%) and
progression was observed in 15 pts (28%). Two pts were not
evaluable for response because of early cessation because of
toxicity. Kaplan–Meier curves for PFS and OS for the 55 pts are
presented in Supplementary Figure S2. Median PFS and median OS
were 6 and 21 months, respectively.
Levels of CEC, CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor
cell, plasma VEGF, sVEGFR-2, SDF-1a and sVCAM-1 were
monitored at baseline and at day 14 (Table 2). Circulating
endothelial cells were identified as CD31
þCD146
þCD45
 7AAD
 
viable events in whole blood by four-color FCM (Jacques et al,
2008). In the present cohort of mRCC pts, the median CEC level at
baseline was 13ml
–1 (range 0–119ml
–1) (Table 2). We analysed
VEGFR-2 (KDR) expression in both CD45
dimCD34
þ7AAD
  and
CD45
 CD34
þ7AAD
  progenitor cell subsets. At baseline, the
CD45
 CD34
þVEGFR2
þ7AAD
  subset represented o0.005% of
circulating CD34
þ progenitor cells. However, the median level
of the CD45
dimCD34
þVEGFR2
þ7AAD
  subset was of 0.5% of
circulating CD34
þ progenitor cells (range 0–24.3%). Median
levels of plasma VEGF, sVEGFR-2, SDF-1a and sVCAM-1 at
baseline were 151pgml
–1 (range 0–1706pgml
–1), 9523pgml
–1
(range 5410–17680pgml
–1), 2726pgml
–1 (range 1210–
3948pgml
–1) and 673ngml
–1 (range 279–1610ngml
–1), respec-
tively (Table 2).
Changes in levels of CEC, CD45
dimCD34
þVEGFR2
þ
progenitor cell and plasma proangiogenic factors under
treatment
Absolute counts of CEC did not significantly change between day
1 and day 14 (P¼0.12) (Table 2). Also, CD45
dimCD34
þVEGFR2
þ
7AAD
  progenitor cell levels were not significantly modified
between day 1 and day 14 (0.5 vs 1.7%, P¼0.08). As expected, TKI
treatment induced an increase in plasma VEGF levels (median
values: 151 vs 273pgml
–1, Po0.0001), which was associated
with a concomitant decrease in plasma sVEGFR2 levels (9523 vs
6229pgml
–1, Po0.0001). Both SDF-1a and sVCAM-1 plasma
levels significantly increased at day 14 (2726 vs 2931pgml
–1,
Po0.0001, 673 vs 720ngml
–1, P¼0.04).
Association between levels of CEC,
CD45
dimCD34
þVEGFR2
þ progenitor cells and plasma
proangiogenic factors and clinical outcome
For all markers, values at baseline and absolute variations between
day 14 and baseline values were compared between non-
progressive (stable and partial responses, n¼38) and progressive
(n¼15) pts. No significant association between CEC, CD45
dim
CD34
þVEGFR2
þ7AAD
  progenitor cell, plasma VEGF, sVEGFR-2,
SDF-1a, sVCAM-1 values and clinical response to TKI treatment
was observed (Table 3).
No significant correlation was observed between baseline CEC,
plasma VEGF, sVEGFR-2, SDF-1a, sVCAM-1 levels and PFS or OS
(Table 3). However, CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor
cell levels at day 1 were associated with PFS and OS. Patients with a
CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cell level at baseline
42% had a higher risk of progression (HR¼2.5, P¼0.01)
(Figure 1A) and had poorer prognosis compared with those pts
whose CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cell levels at
baseline were p2% (HR¼3.3, P¼0.006) (Figures 1B).
No significant association between day 1 and day 14 changes
in CEC, sVEGFR-2, sVCAM-1 levels was observed. Patients whose
CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cell levels were
stable (o 2% or pþ2%) and pts whose CD45
dimCD34
þ
VEGFR2
þ7AAD
  progenitor cell levels increased (X2%) between
baseline and day 14 had a lower risk of progression compared with
pts whose CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cell levels
decreased over the same period (o2%) (HR¼0.3 and 0.5,
respectively, P¼0.03) (Table 3). The variation in VEGF levels
between day 1 and day 14 levels was correlated with OS: pts whose
VEGF values increased more than 270pgml
–1 between day 1 and
day 14 had a poorer OS (HR¼4.9, P¼0.02) (Figure 2). The
Table 1 Description of patient characteristics, treatment and outcome
(n¼55)
No. %
Male 43 78
Age (years)
Median (range) 58 (34–86)
ECOG performance status
02 3 4 2
12 8 5 1
24 7
Histology
Clear cell 43 78
Non-clear cell 12 22
Metastatic sites
11 3 2 4
22 6 4 7
431 6 2 9
Treatment
Sunitinib 46 84
Nexavar 9 16
Best response
PR 10 19
SD 28 53
PD 15 28
MSKCC category
Low 17 31
Intermediate 36 65
Poor 2 4
Abbreviations: ECOG¼Easter Cooperative Oncology Group; MSKCC¼Memorial
Sloan-Kettering Cancer Center; PD¼progressive disease; PR¼partial response;
SD¼stable disease.
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svariation in SDF-1a levels between day 1 and day 14 was correlated
with both PFS and OS (Table 3). Patients whose SDF-1a values
increased between 0 and 600pgml
–1and pts whose SDF-1a values
increased more 600pgml
–1 between day 1 and day 14 had a
lower risk of progression (HR¼0.3 and 0.2, respectively,
P¼0.002) and a lower risk of death (HR¼0.3 and 0.6, respectively,
P¼0.007) compared with pts with decreased SDF-1a values
(Figures 3A and B).
The analysis of associations between levels of CEC, CD45
dim
CD34
þVEGFR2
þ progenitor cells and plasma proangiogenic
factors and clinical outcome was repeated in the 43 pts with
metastatic clear cell carcinoma. As shown in Table 3, baseline
CD45
dimCD34
þVEGFR2
þ7AAD
  progenitor cell levels were
associated with PFS (P¼0.005) and OS (P¼0.001) in this
specific histologic subtype. Similarly, changes in CD45
dimCD34
þ
VEGFR2
þ7AAD
  progenitor cell levels and in SDF-1a levels
between day 1 and day 14 remained associated with PFS (P¼0.05,
P¼0.01). Changes in VEGF and SDF-1a levels were also associated
with OS (P¼0.02, P¼0.009) in pts with metastatic clear cell
carcinoma. Given the preponderance of sunitinib-treated pts, the
analysis was finally repeated in pts with this specific subtype
receiving this single treatment modality (i.e., sunitinib). All of the
above associations remained significant in this small cohort of
34 pts (data not shown).
DISCUSSION
Drugs targeting the VEGF pathway have made a major impact in
the treatment of many types of cancer. Currently, multitargeted
TKI, such as sunitinib or sorafenib, are considered as the standard
of care for therapy in pts with mRCC. However, these agents
clearly demonstrate therapeutic heterogeneity in terms of both
efficacy and toxicity (Escudier et al, 2007; Motzer et al, 2007).
Table 2 Median levels of CEC, CD45
dimCD34
+ VEGFR2
+ cells and plasmatic factors at baseline and day 14
Median levels at
Markers Day 1 Day 14 Changes day 1–day 14 P
a
CEC (ml
–1)1 3 ( n¼55) (0–119)
b 17 (n¼51) (0–157) 0.12
CD45
dimCD34
+ VEGFR2
+ cells (%) 0.5 (n¼52) (0–24.3) 1.7 (n¼48) (0–28.4) 0.08
VEGF (pgml
–1) 151 (n¼54) (0–1706) 273 (n¼49) (1–3765) o0.0001
sVEGFR-2 (pgml
–1) 9523 (n¼54) (5410–17680) 6229 (n¼49) (2609–10393) o0.0001
SDF-1a (pgml
–1) 2726 (n¼54) (1210–3948) 2931 (n¼49) (1400–4433) o0.0001
sVCAM-1 (ngml
–1) 673 (n¼53) (279–1610) 720 (n¼48) (325–1796) 0.04
Abbreviations: CEC¼circulating endothelial cells; SDF-1a¼stroma-derived factor -1a; sVCAM-1¼soluble vascular cell adhesion molecule-1; VEGF¼vascular endothelial
growth factor; VEGFR2¼vascular endothelial growth factor receptor 2.
aWilcoxon signed-rank test.
bRange.
Table 3 Levels of significance of associations between markers and
clinical outcome (response, PFS, OS)
Clinical outcome
Markers Response P
a PFS P
a OS P
a
Day 1
CEC (ml
–1) 0.47 0.69 0.87
CD45
dimCD34
+
VEGFR2
+ cells (%)
0.12 0.01 (0.005) 0.006 (0.001)
VEGF (pgml
–1) 0.12 0.62 0.30
sVEGFR-2 (pgml
–1) 0.16 0.45 0.48
SDF-1a (pgml
–1) 0.15 0.08 0.47
sVCAM-1 (ngml
–1) 0.26 0.35 0.10
Changes day 1–day 14
CEC (ml
–1) 0.27 0.53 0.75
CD45
dimCD34
+
VEGFR2
+ cells (%)
0.83 0.03 (0.05) 0.07
VEGF (pgml
–1) 0.75 0.48 0.02 (0.02)
sVEGFR-2 (pgml
–1) 0.38 0.87 0.92
SDF-1a (pgml
–1) 0.18 0.002 (0.01) 0.007 (0.009)
sVCAM-1 (ngml
–1) 0.65 0.09 0.78
Abbreviations: CEC¼circulating endothelial cells; OS¼overall survival; PFS¼
progression-free survival; SDF-1a¼stroma-derived factor -1a, sVCAM-1¼soluble
vascular cell adhesion molecule-1; VEGF¼vascular endothelial growth factor;
VEGFR2¼vascular endothelial growth factor receptor 2.
aLog rank test. Values in
brackets present levels of significance of associations in the 43 patients with
metastatic clear cell renal carcinoma.
Progression-free survival
3 3 3 5 8 13 19 32 41
1 3 4 11
0%
20%
40%
60%
80%
100%
0
Months from treatment
Day 1 CD45dimCD34+ VEGFR2+  2%
Day 1 CD45dimCD34+ VEGFR2+ > 2%
Log rank test: P = 0.01
At risk
Overall survival
6 9 9 16 24 27 34 38 41
1 3 6 7 11 11
0%
20%
40%
60%
80%
100%
Day 1 CD45dimCD34+ VEGFR2+  2%
Day 1 CD45dimCD34+ VEGFR2+ > 2%
Log rank test: P = 0.006
24 21 18 15 12 9 6 3
0
Months from treatment At risk
24 21 18 15 12 9 6 3
Figure 1 Progression-free survival and OS according to day 1
CD45
dimCD34
þ VEGFR2
þ progenitor cell levels. (A) Progression-free
survival according to day 1 CD45
dimCD34
þ VEGFR2
þ progenitor cell
levels. (B) Overall survival according to day 1 CD45
dimCD34
þ VEGFR2
þ
progenitor cell levels.
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sThus, any biomarker that can predict clinical benefit would be of
great value. To date, none of the expected biological markers, such
as VHL status or VEGF plasma levels, has predicted response to
targeted therapies in mRCC. In the present exploratory study, we
reported the potential interest of a BMD progenitor cell subset,
identified by the CD45
dimCD34
þVEGFR2
þ phenotype in a cohort
of 55 mRCC pts treated with multitargeted TKI. Interestingly, we
observed a correlation between pretreatment CD45
dimCD34
þ
VEGFR2
þ progenitor cell levels phenotype and both PFS and
OS. Early (i.e., within the two first week of treatment) changes in
this progenitor cell subset and in plasma VEGF and SDF-1a levels
were also associated with PFS or OS.
Increased numbers of CEC are considered as a useful marker of
vascular integrity in pts with vascular disorders (Blann et al, 2005)
although their role in tumour neoangiogenesis is less clear. The
rarity of CEC and the controversy concerning the reliability of
their measurement using flow cytometry have yielded conflicting
as well as limited data in cancer pts (Strijbos et al, 2008). In this
study, no association between CEC levels and outcome was
observed. Whether CEC recruitment is an intrinsic characteristic
of some tumour types or a marker of drug class effect or
associations, or whether our method lacks sensitivity to discrimi-
nate different patient outcomes, remains an open question.
Circulating endothelial progenitor can home to sites of
neovascularisation and differentiate into endothelial cells, a
process called postnatal vasculogenesis that was widely proposed
as a mechanism for vascular repair, and tumour metastasis,
neoangiogenesis and growth promotion (Lyden et al, 2001; Spring
et al, 2005; Nolan et al, 2007; Gao et al, 2008). Initial (Lyden et al,
2001) and subsequent studies have indeed identified CEP
incorporation into the endothelial layer of tumour neovessels
(Spring et al, 2005; Nolan et al, 2007), and their critical role in
promoting progression of micro- to macro-metastases (Gao et al,
2008). Other historical data have refuted such a contribution
(Purhonen et al, 2008; Yoder and Ingram, 2009). Despite this
debate, all of these studies agree on the existence of a robust
recruitment of both endothelial and hematopoietic BMD progeni-
tor cells into the neoangiogenic perivasculature, thus supporting
the important role these cells may play in the microenvironmental
molecular and cellular events necessary for tumour invasion and
metastasis. In humans, the phenotypical and functional charac-
terisation of CEP has been hampered by the extreme rarity of these
cells, the lack of consensus on surface marker phenotype, the
important phenotypical overlap with hematopoietic progenitors as
well as the absence of standard in vitro or in vivo assays for
functional characterisation (Yoder and Ingram, 2009). In light of
this, we preferred to refer to the specific sub-population
investigated herein as CD45
dimCD34
þVEGFR2
þ cells (rather than
to CEP). We used a rigorous four-color FCM assay to detect the
circulating CD45
dimCD34
þVEGFR2
þ7AAD
  cell subset in 10ml
of progenitor-enriched whole blood, which characteristics in-
cluded (i) sampling of an important volume of blood, (ii) a pre-
enrichment step, (iii) use of a viability marker (7AAD) and (iv) a
multiple gating strategy (Farace et al, 2007; Taylor et al, 2009). In
contrast to a recent report in pts with non-small cell lung cancer,
we did not detect any sub-population with a CD45
 CD34
þ
VEGFR2
þCD133
  phenotype harbouring size and structural
characteristics of viable cells in our FCM analyses (Vroling et al,
2010). We observed that a high level of CD45
dimCD34
þVEGFR2
þ
progenitor cells (42%) was the single baseline marker associated
with poor PFS (P¼0.01) and OS (P¼0.006) thus suggesting that
baseline CD45
dimCD34
þVEGFR2
þ progenitor cell levels could
allow to discriminate mRCC with poor outcome. Furthermore, we
observed that pts with stable or increased levels of CD45
dim
CD34
þVEGFR2
þ progenitor cells between baseline and day 14
had a lower risk of tumour progression (P¼0.03). However, the
association between day 1 and day 14 changes in CD45
dim
CD34
þVEGFR2
þ progenitor cell levels and OS did not reach
statistical significance (P¼0.07). The present exploratory study
was conducted in a small cohort of 55 pts with mRCC and the
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Figure 2 Overall survival according to changes in day 1–day 14 VEGF
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changes in day 1–day 14 SDF-1a.
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to determine whether CD45
dimCD34
þ VEGFR2
þ progenitor cell
levels were prognostic or predictive. Furthermore, several cell sub-
populations and plasma markers were evaluated, thus introducing
potential biases of multiple testing. When the analysis was
repeated in the 43 pts with metastatic clear cell carcinoma and
in the 34 pts with this single histologic subtype receiving a single
modality of treatment (i.e., sunitinib), these associations between
levels of CD45
dimCD34
þVEGFR2
þ progenitor cells and clinical
outcome remains significant. Biomarkers for RCC would be best
developed in specific histologic subtypes, that is: clear cell RCC or
non-clear cell RCC, especially because the biology of these tumour
types is different and may differently influence the tumour
microenvironment and have different biomarkers relevant to
their predictive and prognostic value. Future studies in a cohort
of mRCC pts with a single tumour histology (i.e., clear cell
carcinoma) receiving a single antiangiogenic treatment (i.e.,
sunitinib) are needed to confirm our results and to determine
the eventual prognostic or predictive value of CD45
dimCD34
þ
VEGFR2
þ progenitor cell levels in this tumour subtype.
Early and more recent studies, including the pivotal phase III
trial of sorafenib in advanced mRCC (Jacobsen et al, 2000;
Escudier et al, 2009), have indicated that baseline VEGF levels
correlate with disease activity and prognosis. However, other
studies have produced inconclusive results. It currently remains
uncertain whether VEGF status alone is an adequate predictive
marker for efficacy of VEGF-targeted therapy in mRCC. Herein,
baseline VEGF and other factor levels did not correlate with PFS or
OS. Unlike a previous study reporting larger changes in VEGF
levels in pts demonstrating objective tumour responses during
sunitinib treatment (Deprimo et al, 2007), we observed that the
magnitude of increase in VEGF levels under treatment was
associated with OS (P¼0.02). Surprisingly, a decrease in SDF-1a
levels was also found to be strongly associated with both PFS
(P¼0.002) and OS (P¼0.007). Plasma factor changes, that is,
increased levels in circulating VEGF and concomitant decreased
levels in sVEGFR2 have been reported as class effects of TKI in pts.
Recently, the observation of increased levels of multiple proangio-
genic factors in sunitinib-treated tumour-free mice has implied a
systemic multi-organ endocrine response to VEGF and PDGF
inhibition in normal tissues (Ebos et al, 2007). Elucidating
underlying mechanisms with respect to the multiple targets
directly or collaterally affected by such agents may prove difficult.
VEGF and SDF-1a are critical regulators governing the mobilisa-
tion and recruitment of a heterogeneous population of BMD
proangiogenic vascular and hematopoietic progenitor cells to
tumours. Initial studies have shown that VEGF-targeted therapy
may inhibit the mobilisation of CEP (Willett et al, 2004) and
induce the increase in SDF-1a blood levels during tumour escape
(Batchelor et al, 2007). Our results do not support these findings
although the dynamics of these processes remain to be determined
under continued therapy. Overall, our results suggest that inadver-
tent changes induced by TKI treatment, that is, upregulation of
VEGF, decrease in SDF-1a, and subsequent changes in BMD
CD45
dimCD34
þ VEGFR2
þ progenitor cell levels are associated
with poor outcome in mRCC pts treated with TKI.
None of the six angiogenesis/endothelial markers evaluated
correlated with tumour response as documented by RECIST. As
angiogenesis/endothelial markers are mainly host-derived, their
changes during antiangiogenic treatment are expected to reflect
the angiogenic–antiangiogenic balance resulting from a complex
interplay between the biological actors of angiogenesis and
the therapeutic agent. These markers may not be as informative
for tumour shrinkage as could be tumour-derived factors. Clinical
results of VEGF-targeted therapy have shown little evidence of
tumour shrinkage and have rather suggested a cytostatic effect,
therefore tumour response criteria by RECIST may not be a good
indicator of clinical benefit of antiangiogenic agents. An impor-
tant issue in identifying biomarkers is the endpoint of the
actual response in pts. Progression-free survival or OS may be
more accurate clinical read-outs for host angiogenesis marker
evaluation.
Escape from antiangiogenic therapy has been demonstrated in
both pre-clinical and clinical settings (Bergers and Hanahan,
2008). Emerging data have implicated evasive resistance mechan-
isms where host adaptive responses circumvent the specific
angiogenic blockade. Low oxygen tension, HIF-1a accumulation
and subsequent SDF-1a and VEGF effectors were reported to
promote angiogenesis and tumour growth via the recruitment of
various proangiogenic BMD sub-populations (Bergers and Hanahan,
2008). Evidence supporting the link between therapy-induced
hypoxia and BMD proangiogenic cell populations stemmed
from a study demonstrating that vascular disrupting agents
(VDA) induced vasculogenic ‘rebounds’ that homed to the
vasculature of treated tumours thereby promoting tumour neo-
vascularisation and subsequent re-growth (Shaked et al, 2006). In a
previous clinical study, we observed the presence of CD45
dim
CD34
þ VEGFR2
þ progenitor cell mobilisation in a small series of
cancer pts included in phase I trial combining a VDA (AVE8062,
Sanofi-Aventis, Antony, France) with chemotherapy (Farace et al,
2007). Further studies are needed to determine whether sub-
populations of BMD progenitors may be biomarkers of response or
resistance to antiangiogenic therapies.
In conclusion, our study shows for the first time an association
between baseline levels of a BMD CD45
dimCD34
þVEGFR2
þ
progenitor cell subset and outcome in mRCC pts treated with
TKI. Also, we present novel data on therapy-induced changes of
CD45
dimCD34
þVEGFR2
þ progenitor cell, VEGF and SDF-1a
levels that were also associated with PFS or OS. Large prospective
studies in a homogeneous cohort of mRCC pts are warranted to
confirm our results as it will allow necessary multivariate analysis
to assess the eventual prognostic or predictive value of these
markers in mRCC pts treated by TKI.
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